Finland Breast Cancer Therapeutics Market Report 2022 to 2030

Finland Breast Cancer Therapeutics Market Analysis

$ 3999

The Finland breast cancer therapeutics market is expected to witness significant growth from $38 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the year 2022-2030. The introduction of new targeted therapies in Finland is one of the main market drivers of Finland's breast cancer therapeutics market. The market is segmented by therapy, by cancer type, and by distribution channel. Some of the major companies in Finland's breast cancer therapeutics market are Montinutra, Amgen, and AstraZeneca.

ID: IN10FIPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Finland AUTHOR: Parul Choudhary

Buy Now

Finland Breast Cancer Therapeutics Market Executive Analysis

The Finland breast cancer therapeutics market size is at around $38 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. The Ministry of Social Affairs and Health and its administrative branch of Finland are proposed to receive appropriations of around $17.32 Bn in 2022. This is around $2.07 Bn less than the budget for 2021. The drop is mostly the result of one-time payments made to offset the expenditures that COVID-19 imposed on the healthcare and social systems. 32% of the budget for the Ministry of Social Affairs and Health and its branch of government will go toward pensions, 28% for basic social assistance and the offset of housing and family expenses, and 16% toward unemployment insurance. Of the allocated funds, grants for the promotion of health and social well-being will account for 2%, healthcare and social welfare provided by municipalities for 3%, and health insurance for 14%.

In Finland, breast cancer is the most prevalent type of cancer in women. It is sometimes seen of as a disease of privileged, Western countries with numerous established risk factors, including unhealthy lifestyles, and a low child population, among others. In addition, there are further unique exposures that are prevalent in contemporary Western society that may be carcinogenic, such as the use of hormonal contraceptives and hair colors by individuals. In Finland, approximately 5000 women are given a breast cancer diagnosis each year. Over half of them fall within the 50- to 69-year-old screening age range. Screening can find about two-thirds of female breast cancers. The remaining breast cancers are discovered in people who have not undergone screening, in people who have undergone screening but whose cancer did not manifest during screening, or in people whose cancer only manifested after mammography. Together, material scientists from Aalto University and breast cancer researchers from the University of Helsinki have created a gel-grown "mini-breast cancer" that will aid in the development of more potent therapeutics for hormone-dependent breast cancer.

finland breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

Numerous new targeted therapies for breast cancer are being developed as a result of recently discovered biology and genetic knowledge. Drugs that stop the multiplication of cancer cells are being developed as part of targeted therapeutics. The rise of Finland's breast cancer therapeutics market is being driven by the country's rising investment in clinical trials.

Market Restraints

Breast cancer treatments can be costly, which could be a deterrent for some people who can't afford the treatments. Despite having a highly valued healthcare system, some regions of Finland may have restricted access to specialized cancer therapies, and the Finland breast cancer therapeutics market growth is being slowed down due to the side effects associated with breast cancer medications.

Competitive Landscape

Key Players

Orion (FIN)
Medix Biochemica (FIN)
Vitabalans Oy (FIN)
Montinutra (FIN)
Amgen
AstraZeneca
Bayer
Johnson and Johnson

Healthcare Policies and Regulatory Landscape

The National Health Insurance System is Finland's public healthcare program. It is very extensive and includes dental expenditures, travel expenses for receiving medical care, and even medical charges. The three levels of care in the system are primary, secondary, and tertiary. At municipal health centers, primary care is concentrated on routine doctor visits and preventative treatment. District hospitals provide advanced specialist care at the secondary and tertiary levels. The national healthcare system in Finland, which is financed by taxes and overseen by the Ministry of Social Affairs and Health, pays for breast cancer treatments. This means that the government covers the expense of breast cancer treatments, so people don't have to pay them out of pocket. For people with breast cancer, the national healthcare system also pays for their diagnostic procedures, operations, radiation treatment, and chemotherapy.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.